Long-term treatments with prednisolone (dose > 10 mg/day for patients > 40 kg in weight and > 5 mg for patients ≤ 40 kg in weight [31]), intravenous immunoglobulins (induction course dose of 2 g/kg with subsequent monthly doses of 1 g/kg/infusion [31]), rituximab, mycophenolate mofetil, methotrexate or azathioprine have all been reported to reduce annualised relapse rate in MOG-AD [31, 33, 37]. This evidence concerns the gene MOG and Alzheimer disease.